Levodopa is named as an intervention in 2 current clinical trials in our Austria and Israel registers. None are recruiting at the moment. The most common phase is Observational. The sponsor with the most trials is Merz Therapeutics GmbH (1). The most-studied condition is Parkinson's Disease. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Gastrointestinal Dopamine Decarboxylase and Levodopa Pharmacokinetics
NCT07793461 · ClinicalTrials.gov ↗ · Parkinson's Disease
|
Phase 4 | Not yet open | Beth Israel Deaconess Medical Center | Israel |
|
Real-world Patient Experiences With Inbrija®
NCT07797790 · ClinicalTrials.gov ↗ · Parkinson Disease (PD), Parkinson's Disease, Off Episodes of Parkinson Disease
|
Observational | Not yet open | Merz Therapeutics GmbH | Austria |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Levodopa. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Evaluating the effect of inhaled levodopa (Inbrija®) for early morning off in Parkinson’s disease
2026-526465-18-00 · CTIS ↗ · Nervous System Diseases
|
Phase 3 | Authorised | Region Hovedstaden | Denmark |
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
1 single-substance product containing Levodopa on the HPRA medicines list.
No entry for Levodopa in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| Merz Therapeutics GmbH | 1 |
| Beth Israel Deaconess Medical Center | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Austria | 1 | 0 |
| Clinical trials in Israel | 1 | 0 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
2 current trials in our Austria and Israel registers name Levodopa as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Merz Therapeutics GmbH (1) and Beth Israel Deaconess Medical Center (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 1 single-substance product containing Levodopa, for example Inbrija 33 mg inhalation powder, hard capsules (Merz Pharmaceuticals GmbH). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Levodopa has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Levodopa works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Levodopa works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Levodopa (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.